112 related articles for article (PubMed ID: 26251224)
1. Evolution: IMiDs to PPMs, revolution in DLBCL?
Nowakowski GS
Blood; 2015 Aug; 126(6):698-700. PubMed ID: 26251224
[TBL] [Abstract][Full Text] [Related]
2. CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL.
Hagner PR; Man HW; Fontanillo C; Wang M; Couto S; Breider M; Bjorklund C; Havens CG; Lu G; Rychak E; Raymon H; Narla RK; Barnes L; Khambatta G; Chiu H; Kosek J; Kang J; Amantangelo MD; Waldman M; Lopez-Girona A; Cai T; Pourdehnad M; Trotter M; Daniel TO; Schafer PH; Klippel A; Thakurta A; Chopra R; Gandhi AK
Blood; 2015 Aug; 126(6):779-89. PubMed ID: 26002965
[TBL] [Abstract][Full Text] [Related]
3. Lenalidomide modulates gene expression in human ABC-DLBCL cells by regulating IKAROS interaction with an intronic control region of SPIB.
Solomon LA; Batista CR; DeKoter RP
Exp Hematol; 2017 Dec; 56():46-57.e1. PubMed ID: 28893618
[TBL] [Abstract][Full Text] [Related]
4. Attacking MALT1 for ABC-DLBCL therapy.
Krappmann D
Oncotarget; 2012 Dec; 3(12):1489-90. PubMed ID: 23455231
[No Abstract] [Full Text] [Related]
5. Signal Pathways and Therapeutic Prospects of Diffuse Large B Cell Lymphoma.
Sun F; Fang X; Wang X
Anticancer Agents Med Chem; 2019; 19(17):2047-2059. PubMed ID: 32009599
[TBL] [Abstract][Full Text] [Related]
6. PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors.
Yahiaoui A; Meadows SA; Sorensen RA; Cui ZH; Keegan KS; Brockett R; Chen G; Quéva C; Li L; Tannheimer SL
PLoS One; 2017; 12(2):e0171221. PubMed ID: 28178345
[TBL] [Abstract][Full Text] [Related]
7. Deciphering the mechanisms of CC-122 resistance in DLBCL via a genome-wide CRISPR screen.
Mo Z; Wood S; Namiranian S; Mizukoshi R; Weng S; Jang IS; Fontanillo C; Baughman JM; Silva-Torres A; Slade M; Khater M; Wang K; Rolfe M; Lu G
Blood Adv; 2021 Apr; 5(7):2027-2039. PubMed ID: 33847741
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of COP9-signalosome (CSN) deneddylating activity and tumor growth of diffuse large B-cell lymphomas by doxycycline.
Pulvino M; Chen L; Oleksyn D; Li J; Compitello G; Rossi R; Spence S; Balakrishnan V; Jordan C; Poligone B; Casulo C; Burack R; Shapiro JL; Bernstein S; Friedberg JW; Deshaies RJ; Land H; Zhao J
Oncotarget; 2015 Jun; 6(17):14796-813. PubMed ID: 26142707
[TBL] [Abstract][Full Text] [Related]
9. AUY922 effectively targets against activated B cell subtype of diffuse large B-cell lymphoma and low-grade lymphoma cells harboring genetic alteration-associated nuclear factor-κB activation.
Tsai HJ; Shih NY; Kuo SH; Cheng AL; Lin HY; Chen TY; Chang KC; Lin SF; Chang JS; Chen LT
Leuk Lymphoma; 2015; 56(9):2674-82. PubMed ID: 25535814
[TBL] [Abstract][Full Text] [Related]
10. CD20-negative diffuse large B-cell lymphomas: biology and emerging therapeutic options.
Castillo JJ; Chavez JC; Hernandez-Ilizaliturri FJ; Montes-Moreno S
Expert Rev Hematol; 2015 Jun; 8(3):343-54. PubMed ID: 25641215
[TBL] [Abstract][Full Text] [Related]
11. A New Therapeutic Era in GCB and ABC Diffuse Large B-cell Lymphoma Molecular Subtypes: A Cell of Origin-Driven Review.
Sandoval-Sus JD; Chavez J; Dalia S
Curr Cancer Drug Targets; 2016; 16(4):305-22. PubMed ID: 26517536
[TBL] [Abstract][Full Text] [Related]
12. Everolimus in diffuse large B-cell lymphomas.
Merli M; Ferrario A; Maffioli M; Arcaini L; Passamonti F
Future Oncol; 2015; 11(3):373-83. PubMed ID: 25675120
[TBL] [Abstract][Full Text] [Related]
13. Constitutive activation of alternative nuclear factor kappa B pathway in canine diffuse large B-cell lymphoma contributes to tumor cell survival and is a target of new adjuvant therapies.
Seelig DM; Ito D; Forster CL; Yoon UA; Breen M; Burns LJ; Bachanova V; Lindblad-Toh K; O'Brien TD; Schmechel SC; Rizzardi AE; Modiano JF; Linden MA
Leuk Lymphoma; 2017 Jul; 58(7):1702-1710. PubMed ID: 27931134
[TBL] [Abstract][Full Text] [Related]
14. The significance of chemokines in diffuse large B-cell lymphoma: a systematic review and future insights.
Huang Q; Liu F; Shen J
Future Oncol; 2019 Apr; 15(12):1385-1395. PubMed ID: 30880459
[TBL] [Abstract][Full Text] [Related]
15. Pharmacologic inhibition of MALT1 protease by phenothiazines as a therapeutic approach for the treatment of aggressive ABC-DLBCL.
Nagel D; Spranger S; Vincendeau M; Grau M; Raffegerst S; Kloo B; Hlahla D; Neuenschwander M; Peter von Kries J; Hadian K; Dörken B; Lenz P; Lenz G; Schendel DJ; Krappmann D
Cancer Cell; 2012 Dec; 22(6):825-37. PubMed ID: 23238017
[TBL] [Abstract][Full Text] [Related]
16. Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors.
Gopalakrishnan R; Matta H; Tolani B; Triche T; Chaudhary PM
Oncogene; 2016 Apr; 35(14):1797-810. PubMed ID: 26119939
[TBL] [Abstract][Full Text] [Related]
17. Proteasomal cysteine deubiquitinase inhibitor b-AP15 suppresses migration and induces apoptosis in diffuse large B cell lymphoma.
Jiang L; Sun Y; Wang J; He Q; Chen X; Lan X; Chen J; Dou QP; Shi X; Liu J
J Exp Clin Cancer Res; 2019 Nov; 38(1):453. PubMed ID: 31694672
[TBL] [Abstract][Full Text] [Related]
18. FOXP1 suppresses immune response signatures and MHC class II expression in activated B-cell-like diffuse large B-cell lymphomas.
Brown PJ; Wong KK; Felce SL; Lyne L; Spearman H; Soilleux EJ; Pedersen LM; Møller MB; Green TM; Gascoyne DM; Banham AH
Leukemia; 2016 Mar; 30(3):605-16. PubMed ID: 26500140
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological DNA demethylation restores SMAD1 expression and tumor suppressive signaling in diffuse large B-cell lymphoma.
Stelling A; Wu CT; Bertram K; Hashwah H; Theocharides APA; Manz MG; Tzankov A; Müller A
Blood Adv; 2019 Oct; 3(20):3020-3032. PubMed ID: 31648327
[TBL] [Abstract][Full Text] [Related]
20. DCZ3301, a novel cytotoxic agent, inhibits proliferation in diffuse large B-cell lymphoma via the STAT3 pathway.
Sun X; Li B; Xie B; Xu Z; Chang G; Tao Y; Zhang Y; Chang S; Wang Y; Yu D; Xie Y; Li T; Wang H; Chen G; Hu L; Hou J; Zhang Y; Xiao W; Gao L; Shi J; Zhu W
Cell Death Dis; 2017 Oct; 8(10):e3111. PubMed ID: 29022919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
